Investors

Company Profile

Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.

Financial Reports

Q2 Half Year Report 2021

August 5, 2021

Q1 Report 2021

May 6, 2021

Investor presentations

ObsEva Investor Presentation – April 2019

ObsEva Short Report 2018

1 3 4 5

Press Releases

ObsEva to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

press release

September 7, 2021

GENEVA, Switzerland September 7, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…

Read more

ObsEva Announces Second Quarter 2021 Financial Results and Business Update

press release

August 5, 2021

-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-…

Read more

ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF

press release

August 4, 2021

– A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical…

Read more
1 2 3 4 65

General Meetings

ObsEva Annual General Meeting 2021

May 28, 2021

Read more

ObsEva Annual General Meeting 2020

June 9, 2020

Read more
1 2 3

Upcoming Events

Sorry, there are no events available yes.

 

Contacts

ObsEva Switzerland Office

Chemin des Aulx,12

1228, Plan-Les-Ouates, Geneva, Switzerland

+41 (0)22 552 3840


contact@obseva.ch

Media

Shauna Dillon

+41 (0)22 552 1550 Office

+41 79 360 3533 Mobile

shauna.dillon@obseva.ch

Investor relations


.


Joyce Allaire

+1 (617)-435-6602

ir@obseva.ch

Clinical studies




clinicaltrials@obseva.ch

HR Office

Charlotte Cadoux


charlotte.cadoux@obseva.ch

CEO Office

+41 (0)22 552 1550


shauna.dillon@obseva.ch

 

Sign up for news

 
 

    * Type:


    InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












    Read our privacy policy here.


     

    Are you sure you want to leave ObsEva.com?

    We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

    Continue to link

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue

    Disclaimer

    Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

    Continue